sp0010">HRQoL was measured at baseline and 3, 12, and 24 months or end of study (EOS) in 7243 patients aged <75 years using the EuroQol 3-level, group 5-dimension index (EQ-5D). Linear mixed effects models for repeated measures were used to examine treatment differences in HRQoL overall, stratified by angiography status, and among patients who did and did not have non-fatal events.
sp0015">No baseline differences in HRQoL were seen between patients randomized to prasugrel (n = 3620) or clopidogrel (n = 3623). At 24 months, remaining patients assigned to prasugrel (n = 1450) vs. clopidogrel (n = 1443) had higher EQ-5D index scores (86.4 vs. 84.9, P = .01). Mixed effects models found no difference in EQ-5D scores among prasugrel and clopidogrel patients overall across subgroups stratified by angiography status. However, among patients with non-fatal clinical events, patients on clopidogrel reported a larger decrement in HRQoL than patients on prasugrel (79.5 ± 18.1 vs. 80.6 ± 18.0; P = .02).
sp0020">Overall, there was no difference in HRQoL outcomes among patients receiving prasugrel vs. clopidogrel. However, the differential effects of the treatments among patients with non-fatal events require further investigation.